Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Agios Pharmaceuticals (AGIO) Invested Capital (2016 - 2025)

Historic Invested Capital for Agios Pharmaceuticals (AGIO) over the last 14 years, with Q4 2025 value amounting to $1.2 billion.

  • Agios Pharmaceuticals' Invested Capital fell 2257.31% to $1.2 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $1.2 billion, marking a year-over-year decrease of 2257.31%. This contributed to the annual value of $1.2 billion for FY2025, which is 2257.31% down from last year.
  • Per Agios Pharmaceuticals' latest filing, its Invested Capital stood at $1.2 billion for Q4 2025, which was down 2257.31% from $1.3 billion recorded in Q3 2025.
  • In the past 5 years, Agios Pharmaceuticals' Invested Capital registered a high of $2.3 billion during Q1 2021, and its lowest value of $660.5 million during Q2 2024.
  • Over the past 5 years, Agios Pharmaceuticals' median Invested Capital value was $1.2 billion (recorded in 2022), while the average stood at $1.2 billion.
  • In the last 5 years, Agios Pharmaceuticals' Invested Capital surged by 26728.51% in 2021 and then plummeted by 4742.5% in 2022.
  • Agios Pharmaceuticals' Invested Capital (Quarter) stood at $1.3 billion in 2021, then dropped by 14.8% to $1.1 billion in 2022, then fell by 26.33% to $811.0 million in 2023, then surged by 90.0% to $1.5 billion in 2024, then dropped by 22.57% to $1.2 billion in 2025.
  • Its Invested Capital stands at $1.2 billion for Q4 2025, versus $1.3 billion for Q3 2025 and $1.4 billion for Q2 2025.